Withdrawal screening definition

Withdrawal screening means the evaluation of a patient’s condition as it relates to current or potential withdrawal from alcohol or another substance.
Sample 1Sample 2Sample 3
Withdrawal screening means the evaluation of a patient’s condition as it relates to current or potential withdrawal from alcohol or another sub- stance.
Sample 1

Examples of Withdrawal screening in a sentence

  • Withdrawal screening, admission, and signs of trauma.[Statutory Authority: RCW 71.24.037, 71.05.560, 71.34.380, 18.205.160,71.24.037 and chapters 71.05, 71.24, and 71.34 RCW.

  • Nietzsche thinks of this will to create something beyond oneself, this will to self-overcoming, against spirit’s will to pure knowledge which is ultimately life-denying.

  • This personnel training must include the following topics: WAC 388-877-1100(4)(a) Substance use disorders; WAC 388-877-1100(4)(b) Infectious diseases, to include hepatitis and tuberculosis (TB); and WAC 388-877-1100(4)(c) Withdrawal screening, admission, and signs of trauma.

  • Withdrawal screening tools7 8 can be useful for those who are not experienced in the clinical assessment of withdrawal severity.In those presenting with a less clear history of dependence, a more prolonged period of careful assessment and consideration of the aims of treatment may be prudent, for example where people report using opioid analgesia rather than heroin.

  • Withdrawal screening, admission, and signs of trauma.)) AMENDATORY SECTION (Amending WSR 19-09-062, filed 4/16/19, effective 5/17/19) WAC 246-341-1108 Residential substance use disorder treatment services—General.

Related to Withdrawal screening

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

  • Additional SDU Study means a deliverability study that a Developer may elect to pursue as that term is defined in OATT Section 25 (OATT Attachment S). For purposes of Section 23.4.5 of this Attachment H, “Affiliated Entity” shall mean, with respect to a person or Entity:

  • Semi-annual (2/Year) sampling frequency means the sampling shall be done during the months of June and December, unless specifically identified otherwise.

  • Screening means the evaluation process used to identify an individual's ability to perform activities of daily living and address health and safety concerns.

  • Election campaign means any campaign in support of or in

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Yearly (1/Year) sampling frequency means the sampling shall be done in the month of September, unless specifically identified otherwise in the effluent limitations and monitoring requirements table.

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.